On the Record · GSK
GSK acquisitions, on the record
The businesses GSK bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Bellus HealthWord for word“Our activity in 2023 included the acquisition of Bellus Health and Aiolos Bio1, which both further strengthen our respiratory pipeline, and the signing of licence agreements with Janssen and Hansoh Pharma, in infectious diseases and oncology.” 20-F for 2023 | acquisition | — | — |
Aiolos BioWord for word“In early 2024, we acquired Aiolos Bio, Inc.” 20-F for 2023 | acquisition | In early 2024 | — |
Read from GSK’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.